In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans

References

• BROCKMOLLER, J., KIRCHHEINER, J., MEISEL, C. and ROOTS, I., 2000, Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics, 1, 125–151.
   PubMedGoogle Scholar
• CHANG, J., CHADWYCK, R. W., ALLISON, J. C., HAYES, Y. O., TALLEY, D. L. and AUTRY, C. E., 1994, Microbial succession and intestinal enzyme activities in the developing rat. Journal of Applied Bacteriology, 77, 709–718.
   PubMedGoogle Scholar
• CLOZEL, M., RAMUZ, H., CLOZEL, J.P., BREU, V., HESS, P., LDFFLER, B. M., COASSOLO, P. and Roux, S., 1999, Pharmacology of tezosentan, new endothelin receptor antagonist for parenteral use. Journal of Pharmacology and Experimental Therapeutics, 290, 840–846.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L. and STRESSER, D. M., 2000, Fluorimetric screening for metabolism-based drug—drug interactions. Journal of Pharmacology and Toxicology Methods, 44, 325–331.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE, J., CLOZEL, M. and VAN GIERSBERGEN, P. L. M., 2002a, Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. Journal of Cardiovascular Pharmacology, 39, 795–802.
   PubMedGoogle Scholar
• DINGEMANSE, J., CLOZEL, M. and VAN GIERSBERGEN, P. L. M., 2002b, Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. British Journal of Clinical Pharmacology, 53, 355–362.
   PubMedGoogle Scholar
• DOUMAS, B. T., BAYSE, D. D., CARTER, R. J., PETERS, T. and SCHAFFE R., 1981, A candidate reference method for determination of total protein in serum. I. Development and validation. Clinical Chemistry, 27, 1642–1650.
   Google Scholar
• FISHER, M. B., PAINE, M. F., STRELEVITZ, T. J. and WRIGHTON, S. A., 2001, The role of hepatic and extrahepatic UDP-glucuronyltransferases in human drug metabolism. Drug Metabolism Reviews, 33, 273–297.
   PubMed Web of Science ®Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker).
   Google Scholar
• HOPFGARTNER, G., VETTER, W., MEISTER, W. and RAMUZ, H., 1996, Fragmentation of bosentan (Ro 47-0203) in ionspray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ion. Journal of Mass Spectrometry, 31,69–76.
   Google Scholar
• JOHNSON, A. M., ROHLFS, E. M. and SILVERMAN, L. M., 2001, Proteins. In Tietz Fundamentals of Clinical Chemistry, 5th edn. C. A. Burtis and E. R. Ashwood (eds) (Philadelphia: W. B. Saunders), pp. 325–351.
   Google Scholar
• KADDOURA, S. and POOLE-WILSON, P. A., 1996, Endothelin-1 in heart failure. A new therapeutic target? Lancet, 348,418–419.
   PubMedGoogle Scholar
• KRIETER, P. A., COLLETTI, A. E., MILLER, R. R. and STEARNS, R. A., 1995, Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. Journal of Pharmacology and Experimental Therapeutics, 273, 816–822.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDAL, R. J., 1951, Protein measurement with Folin phenol reagents. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• LüscHER, T. F. and BARTON, M., 2000, Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 102, 2434–2440.
   Google Scholar
• MILLER, V. P., STRESSER, D. M., BLANCHARD, A. P., TURNER, S. and CRESPI, C. L., 2000, Fluorimetric high-throughput screening for inhibitors of cytochrome P450. Annals of the New York Academy of Sciences, 919, 26–32.
   PubMedGoogle Scholar
• PERRIER, L., BOURRIE, M., MARTI, E., TRONQUET, C., MASSE D., BERGER Y., MAGDALOU, J. and FABRE, G., 1994, In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. Journal of Pharmacology and Experimental Therapeutics, 271, 91–99.
   Google Scholar
• RABELINK, T. J., KAASJAGER, K. A., STROES, E. S. and KOOMANS, H. A., 1996, Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney International, 50, 1827–1833.
   PubMed Web of Science ®Google Scholar
• REDMAN, A. R., 2001, Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy, 21, 235–242.
   PubMed Web of Science ®Google Scholar
• ROWLAND, M. and TOZER, T. N., 1995, Clinical Pharmacokinetics: Concepts and Applications, 3rd edn (Baltimore: Williams & Wilkins).
   Google Scholar
• RUBIN, L. J., BADESCH, D. B., BARST, R. J., GALit, N., BLACK, C. M., KEOGH, A., PULIDO, T., FROST, A., Roux, S., LECONTE, I., LANDZBERG, M. and SIMONNEAU, G., 2002, Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine, 346, 896–903.
   PubMed Web of Science ®Google Scholar
• SEGLEN, P. O., 1973, Preparation of rat liver cells. 3. Enzymatic requirements for tissue dispersion. Experimental Cell Research, 82, 391–398.
   PubMed Web of Science ®Google Scholar
• TONG, W., CHOWDHURY, S. K., CHEN, J. C., ZHONG, R., ALTON, K. B. and PATRICK, J. E., 2001, Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process. Rapid Communications in Mass Spectrometry, 15, 2085–2090.
   PubMedGoogle Scholar
• VAN GIERSBERGEN, P. L. M., BODIN, F. and DINGEMANSE, J., 2002, Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. European Journal of Clinical Pharmacology, 58, 243–245.
   Google Scholar
• VANE, F. M., BUGGE, C. J., RODRIGUEZ, L. C., ROSENBERGER, M. and DORAN, T. I., 1990, Human biliary metabolites of isotretinoin: identification, quantification, synthesis, and biological activity. Xenobiotica, 20, 193–207.
   PubMed Web of Science ®Google Scholar
• VON BAHR, C., GROTH, C. G., JANSSON, H., LUNDGREN, G., LIND, M. and GLAUMANN, H., 1980, Drug metabolism in human liver in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapeutics, 27, 711–725.
   PubMedGoogle Scholar
• WEBER, C., GASSER, R. and HOPFGARTNER, G., 1999, Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metabolism and Disposition, 27, 810–815.
   PubMed Web of Science ®Google Scholar